Benign focal seizures of adolescence

Summary

Benign focal seizures of adolescence (MONDO:0015471) is a disease. A subtype of epilepsy syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign focal seizures of adolescence
Mondo ID	MONDO:0015471
Orphanet	1544
ICD-11	1800285392
SNOMED CT	715425000
UMLS	C4275141
MedGen	896830
GARD	0018728
Is cancer (heuristic)	no

Also known as: adolescent benign focal crisis

Disease family

This is a subtype of epilepsy syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › epilepsy › epilepsy syndrome › benign focal seizures of adolescence

Related subtypes (7): adolescence-adult electroclinical syndrome, neonatal epilepsy syndrome, infantile epilepsy syndrome, childhood-onset epilepsy syndrome, neonatal/infantile epilepsy syndrome, myoclonic epilepsy, variable age epilepsy syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.